ClinicalTrials.gg
RecruitingNCT07248371Updated Nov 25, 2025

Validating Integrative Multi-omics Approaches in Metabolic Syndrome-related Diseases

An observational study in Metabolic Syndrome (MetS), Obesity & Overweight and Cardiovascular Diseases (CVD), sponsored by Chang Gung Memorial Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by Chang Gung Memorial Hospital · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
6,266
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Metabolic Syndrome with a site in Taiwan — 15 open to participants now, 15 under way, none of them phase 3. Metabolic Syndrome · Taiwan.

Planned enrollment
3rd of 28
6,266 · median 295
Started
2025
with 5 others
Observational
29 of 69
5 open now
Primary completion
2028-09
later than 12 of 14 live
Registered
63rd of 69
by date
Lead sponsor
5 of 69
Chang Gung Memorial Hospital

Among the 69 studies in Metabolic Syndrome with a site in Taiwan, this one is the 3rd largest by planned enrollment of the 28 observational ones that give a count, is one of 6 that started in 2025, is one of 29 observational ones, reaches primary completion later than 12 of the 14 other live ones, and was the 63rd registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

15 of the 69 studies in Metabolic Syndrome with a site in Taiwan are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Metabolic Syndrome with a site in Taiwan, or all of them as a file.
02

Study summary

This study aims to validate integrative multi-omics approaches for understanding complications related to metabolic syndrome. By combining genetic, transcriptomic, metabolomic, and microbiome data from participants with and without metabolic syndrome, the research seeks to determine which biological factors predict disease progression and how these insights can inform precision prevention and treatment strategies for metabolic disorders.

Read the detailed description

This longitudinal, multi-center study is designed to validate integrative multi-omics methodologies for predicting disease progression and complications in metabolic syndrome. Participants will be recruited from all branches of Chang Gung Memorial Hospitals. Individuals who meet the diagnostic criteria for metabolic syndrome will constitute the study group, while age- and sex-matched individuals without metabolic syndrome will serve as controls.

The study will collect peripheral blood, urine, and stool samples for comprehensive multi-omics profiling, including genomics (DNA sequencing), transcriptomics (RNA sequencing), metabolomics (serum and urine metabolite profiling), and microbiomics (stool microbiota analysis). Blood samples (10 mL) will be obtained annually for genetic and metabolomic analyses, while urine (30 mL) and stool (1 mL) samples will be used to assess metabolite and microbial signatures. These biospecimens will be linked with participants' longitudinal clinical data and laboratory test results retrieved from the Chang Gung Research Database (CGRD), providing a unified framework for integrative analysis.

Data integration will utilize advanced bioinformatics pipelines and systems biology tools to identify multi-layered molecular networks associated with disease onset and progression. Analytical methods include dimensionality reduction, clustering, and machine-learning-based feature selection to construct predictive models for metabolic complications such as cardiovascular disease, chronic kidney disease, and fatty liver disease. Identified biomarkers and pathways will be validated internally and cross-compared with pre-existing data from the "Integrated Smart Healthcare Database for Obesity."

All data will be de-identified and securely stored on institutional servers with restricted access. Each participant will be assigned a unique study code to ensure confidentiality. Data linkage between omics datasets and clinical outcomes will be performed through encrypted, privacy-preserving algorithms under the supervision of the institutional data governance committee. The study adheres to the ethical standards set by the Institutional Review Board, ensuring participant protection throughout data collection, analysis, and dissemination.

03

Conditions studied

  • Metabolic Syndrome (MetS)
  • Obesity & Overweight
  • Cardiovascular Diseases (CVD)
  • Chronic Kidney Disease
  • Nonalcoholic Fatty Liver Disease
  • Healthy

Keywords

  • Metabolic Syndrome
  • Multi-Omics
  • Precision Medicine
  • Metabolomics
  • Genomics
  • Transcriptomics
  • Microbiome
  • Machine Learning
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will be recruited from outpatient clinics at Chang Gung Memorial Hospitals in Taiwan. Recruitment will occur through the Departments of Endocrinology, Cardiology, Cardiac Surgery, Nephrology, and Gastroenterology. The study population will include adults receiving routine clinical care at these sites, representing both individuals with metabolic syndrome and those without the condition who serve as healthy controls. This hospital-based community cohort reflects a diverse urban and suburban Taiwanese population, enabling comprehensive multi-omics analysis of metabolic syndrome-related diseases within a real-world clinical setting.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals (male or female) aged 20 years or older
  • Willing and able to provide written to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women
  • Patients with end-stage renal disease receiving hemodialysis or peritoneal dialysis
  • Individuals currently undergoing active cancer treatment
  • Recipients of any organ transplantation
  • Patients diagnosed with dementia
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
6,266 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • whole cohort

    Participants who meet the diagnostic criteria for metabolic syndrome, as defined by the International Diabetes Federation (IDF) and/or ATP III guidelines and those participants without metabolic syndrome who are matched to the study group by age and sex. These individuals will undergo annual biospecimen collection (blood, urine, and stool) and longitudinal clinical follow-up to identify molecular signatures associated with disease progression and metabolic complications.

    Other: No intervention

Interventions

  • OtherNo intervention

    no intervention

06

What researchers measure

Primary outcomes

  1. Identification and validation of multi-omics biomarkers associated with metabolic syndrome and its complications

    Comprehensive integration of genomic, transcriptomic, metabolomic, and microbiome datasets to identify molecular signatures predictive of metabolic syndrome progression and related complications (e.g., cardiovascular disease, chronic kidney disease, fatty liver).

    Time frame: 5 years

Secondary outcomes

  1. Longitudinal changes in metabolomic and microbiome profiles

    Evaluation of yearly changes in serum metabolite and gut microbiota composition and their correlation with metabolic parameters such as fasting glucose, triglycerides, HDL-C, and blood pressure.

    Time frame: Annually for 5 years

  2. Association between omics-derived biomarkers and clinical outcomes

    Analysis of associations between identified omics signatures and incident cardiometabolic events (e.g., myocardial infarction, heart failure, renal impairment, fatty liver progression).

    Time frame: Up to 5 years

  3. Development of an integrative risk prediction model

    Construction and internal validation of a machine-learning-based model incorporating multi-omics and clinical data to predict metabolic syndrome-related complications.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • Chang Gung Memorial Hospitals, Linkou
    Taoyuan, Taiwan
    Recruiting
08

References and documents

Publications

  • Hsu PW, Yeh CH, Lo CJ, Tsai TH, Chan YH, Chou YJ, Yang NI, Cheng ML, Sheu WH, Lai CC, Sytwu HK, Tsai TF. Trans-omics analyses identify the biochemical network of LPCAT1 associated with coronary artery disease. Biomark Res. 2025 Aug 20;13(1):107. doi: 10.1186/s40364-025-00821-y. PubMed 40830908 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Sep 2028, 39 months after the start.

Of 150 non-industry observational studies under Metabolic Syndrome, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 106. This study's planned 39 months is close to that.

Counting every sponsor, half of 161 studies reached it within 42 months; a quarter within 18 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Nov 25, 2025
StartActual
Jun 9, 2025
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2035
Last update
Nov 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07248371
Responsible party
Sponsor
First posted
Nov 25, 2025
Start date
Jun 9, 2025
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2035 (estimated)
Last update
Nov 25, 2025

Study contacts

Chi-Hsiao Yeh, MD PhD
Contact
yehccl@cgmh.org.tw
+886-3-3281200 ext. 2118

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion